Loading
NASDAQHealthcareMedical - Devices
Latest quote
$6.07
−$0.02 · -0.33%
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Previous close
$6.07
−$0.02 · -0.33%
After-hours
$6.06
−$0.01 · -0.16%
Oct 7, 7:36 PM ET
Regular session · ET · Market data may be delayed.
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Day range
Current $6.07
52-week range
Current $6.07
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
46
Fair Value
Sentiment
66
Bullish
Risk
75
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Day range
Current $6.07
52-week range
Current $6.07
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 574.25K USD | 294.17K USD |
| Gross profit | — | — | — | 574.25K USD | 294.17K USD |
| Research and development | 1.91M USD | 2.21M USD | 2.52M USD | 2.75M USD | 2.34M USD |
| Selling, general, and administrative | 7.29M USD | 9.34M USD | 12.64M USD | 12.47M USD | 10.72M USD |
| Operating expenses | 7.29M USD | 9.34M USD | 12.64M USD | 12.47M USD | 10.72M USD |
| Interest income | 156.53K USD | 298.12K USD | 428.39K USD | 10.97K USD | — |
| Interest expense | 14.37K USD | 10.11K USD | — | — | — |
| Depreciation and amortization | 323.65K USD | 339.56K USD | 359.06K USD | 240.89K USD | 123.69K USD |
| Operating income | −7.29M USD | −9.34M USD | −12.64M USD | −11.9M USD | −10.42M USD |
| Net income | −7.15M USD | −13.39M USD | −12.21M USD | −12.03M USD | −10.42M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$1.50
75.29% downsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 4, 2026 | 1:5 | — | — |
Stock split | Oct 20, 2025 | 1:10 | — | — |
Stock split | Jun 9, 2025 | 1:8 | — | — |
Stock split | Oct 5, 2023 | 1:10 | — | — |
Stock split | Oct 15, 2019 | 1:15 | — | — |
Stock split | Apr 14, 2015 | 1:50 | — | — |
Effective Aug 4, 2026
1:5
Effective Oct 20, 2025
1:10
Effective Jun 9, 2025
1:8
Effective Oct 5, 2023
1:10
Effective Oct 15, 2019
1:15
Effective Apr 14, 2015
1:50
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
